Rheumatology Advances in Practice最新文献

{"title":"Muscular polyarteritis nodosa with fasciitis and upper extremity involvement.","authors":"Setsuko Oyama, Hiroyuki Yamashita, Misa Yamaji, Toshiaki Kobayashi, Akatsuki Kubota, Jun Shimizu, Tamiko Takemura, Hiroshi Kaneko","doi":"10.1093/rap/rkae088","DOIUrl":"10.1093/rap/rkae088","url":null,"abstract":"","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 3","pages":"rkae088"},"PeriodicalIF":2.1,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11297502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unusual reaction to a local corticosteroid injection to the heel: Tachon's syndrome?","authors":"Sidra Hussain, Ali S Jawad","doi":"10.1093/rap/rkae092","DOIUrl":"10.1093/rap/rkae092","url":null,"abstract":"","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 3","pages":"rkae092"},"PeriodicalIF":2.1,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11319641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: The diagnosis and management of systemic autoimmune rheumatic disease-related interstitial lung disease: British Society for Rheumatology guideline scope.","authors":"","doi":"10.1093/rap/rkae085","DOIUrl":"https://doi.org/10.1093/rap/rkae085","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/rap/rkae056.].</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 3","pages":"rkae085"},"PeriodicalIF":2.1,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11283306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: The influence of deprivation in the outcomes of psoriatic arthritis within the UK-utilizing Outcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS) data.","authors":"","doi":"10.1093/rap/rkae079","DOIUrl":"10.1093/rap/rkae079","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/rap/rkae051.].</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 3","pages":"rkae079"},"PeriodicalIF":2.1,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11246160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.","authors":"Louise Mercer, Abhishek Abhishek, Akhila Kavirayani, Alison Ahmed, Alan Davidson, Amy Foulkes, Claire Jones, Clare Nash, Emily Rose-Parfitt, Emmandeep Dhillon, Genevieve Zabate, Helen Twohig, Hope De Vere, Jennifer Scott, John Reynolds, Julia Holmes, Karen Hartley, Kishore Warrier, Kataryzna Nowak, Kate Parsons, Katie Bechman, Lisa Bray, Madura Adikari, Natasha Wood, Nicola Faithfull, Nicola Gullick, Pratyasha Saha, Rebecca Heaton, Samundeeswari Deepak, Samantha Hider, Sameena Khalid, Sanaa Suleiman Said, Sarah Ryan, Stuart Kyle, Subhra Raghuvanshi, Su-Yin Tan, Vinay Shivamurthy, James Galloway","doi":"10.1093/rap/rkae077","DOIUrl":"10.1093/rap/rkae077","url":null,"abstract":"<p><p>This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology's 'Creating clinical guidelines: our protocol', updated 2023.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 3","pages":"rkae077"},"PeriodicalIF":2.1,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between obesity and patient-reported outcome measures in people with polymyalgia rheumatica.","authors":"Ian C Scott, Ram Bajpai, Samantha L Hider, Toby Helliwell, Christian D Mallen, Sara Muller","doi":"10.1093/rap/rkae081","DOIUrl":"10.1093/rap/rkae081","url":null,"abstract":"<p><strong>Objective: </strong>To examine the association between obesity and patient-reported outcome measures (PROMs) in a primary care-based cohort of people with PMR.</p><p><strong>Methods: </strong>The PMR Cohort Study recruited people with incident PMR from 382 general practices. Self-completed questionnaires (0, 12, 24 months) captured a range of PROMs for pain, stiffness, anxiety, depression, fatigue, function and quality of life, alongside data on BMI. People were categorized as underweight/normal weight (BMI < 25kg/m²), overweight (25-29.99 kg/m²) or obese (≥30 kg/m²). Piecewise, multilevel, linear mixed-effects regression models examined relationships between BMI categories and PROMs over time, adjusting for confounding variables. Chi-squared tests examined the relationship between obesity and glucocorticoid persistence.</p><p><strong>Results: </strong>644 people with PMR were included. At baseline, 33.9% were normal/underweight, 40.6% overweight and 25.5% obese. Compared with normal/underweight people, those with obesity had significantly worse scores for the following: pain and stiffness at 12 months; fatigue at 12 and 24 months; depression at baseline; physical function at all time points; and quality of life at baseline and 12 months. They also had significantly smaller improvements in stiffness (1.13 units on an 11-point numeric rating scale; <i>P </i>=<i> </i>0.001) and physical function (0.14 units measured using the modified Health Assessment Questionnaire; <i>P </i>=<i> </i>0.025) between 0 and 12 months. BMI categories did not relate to persistent glucocorticoid use at 12 months (<i>P </i>=<i> </i>0.110) or 24 months (<i>P </i>=<i> </i>0.166).</p><p><strong>Conclusion: </strong>Obesity associates with poorer outcomes for a range of PROMs in people with PMR. Consideration should be given to providing weight management support to people with PMR and obesity.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 3","pages":"rkae081"},"PeriodicalIF":2.1,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated quantification of wrist bone marrow oedema, pre- and post-treatment, in early rheumatoid arthritis.","authors":"Chungwun Yiu, James Francis Griffith, Fan Xiao, Lin Shi, Bingjing Zhou, Su Wu, Lai-Shan Tam","doi":"10.1093/rap/rkae073","DOIUrl":"10.1093/rap/rkae073","url":null,"abstract":"<p><strong>Objective: </strong>Bone inflammation (osteitis) in early RA (ERA) manifests as bone marrow oedema (BME) and precedes the development of bone erosion. In this prospective, single-centre study, we developed an automated post-processing pipeline for quantifying the severity of wrist BME on T2-weighted fat-suppressed MRI.</p><p><strong>Methods: </strong>A total of 80 ERA patients [mean age 54 years (s.d. 12), 62 females] were enrolled at baseline and 49 (40 females) after 1 year of treatment. For automated bone segmentation, a framework based on a convolutional neural network (nnU-Net) was trained and validated (5-fold cross-validation) for 15 wrist bone areas at baseline in 60 ERA patients. For BME quantification, BME was identified by Gaussian mixture model clustering and thresholding. BME proportion (%) and relative BME intensity within each bone area were compared with visual semi-quantitative assessment of the RA MRI score (RAMRIS).</p><p><strong>Results: </strong>For automated wrist bone area segmentation, overall bone Sørensen-Dice similarity coefficient was 0.91 (s.d. 0.02) compared with ground truth manual segmentation. High correlation (Pearson correlation coefficient <i>r</i> = 0.928, <i>P</i> < 0.001) between visual RAMRIS BME and automated BME proportion assessment was found. The automated BME proportion decreased after treatment, correlating highly (<i>r</i> = 0.852, <i>P</i> < 0.001) with reduction in the RAMRIS BME score.</p><p><strong>Conclusion: </strong>The automated model developed had an excellent segmentation performance and reliable quantification of both the proportion and relative intensity of wrist BME in ERA patients, providing a more objective and efficient alternative to RAMRIS BME scoring.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 3","pages":"rkae073"},"PeriodicalIF":2.1,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11194532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141446914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals.","authors":"Andre L Ribeiro, Shikha Singla, Vinod Chandran, Nicholas Chronis, Wilson Liao, Christine Lindsay, Enrique R Soriano, Philip J Mease, Fabian Proft","doi":"10.1093/rap/rkae074","DOIUrl":"10.1093/rap/rkae074","url":null,"abstract":"<p><strong>Objectives: </strong>This study contributes to the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)'s effort to define 'difficult-to-treat' PsA (D2T-PsA), leveraging insights of healthcare professionals who are GRAPPA members. The primary objective is to inform GRAPPA's D2T PsA project, ensuring the consensus definition reflects clinical experience and expertise.</p><p><strong>Methods: </strong>An online survey was conducted among GRAPPA's healthcare professionals managing PsA patients. The survey covered demographic details, structured questions, and open-ended queries to gather comprehensive insights into the experts' viewpoints.</p><p><strong>Results: </strong>About 223 physicians completed the survey, comprising 179 (80.2%) rheumatologists and 40 (17.9%) dermatologists. The majority, 184 (82.5%), favoured establishing distinct definitions for D2T-PsA and complex-to-manage PsA (C2M-PsA). Furthermore, 202 (90.5%) supported a definition that includes objective inflammation signs (clinical, laboratory, imaging, among others). However, opinions varied on the criteria for prior treatment failures, with most (93, 41.7%) favouring a definition that includes at least one conventional synthetic disease-modifying anti-rheumatic drug and two or more biological- or targeted-synthetic-DMARDs with different mechanisms of action.</p><p><strong>Conclusion: </strong>The survey reveals a majority opinion among GRAPPA experts favouring the differentiation between D2T-PsA and C2M-PsA, and the inclusion of objective inflammatory markers in these definitions. However, there is less than 50% agreement on the specific treatment failure criteria, particularly regarding the number of therapies needed to classify PsA as D2T. These findings suggest a need for continued discussion to reach a more unified approach in defining D2T-PsA, reflecting the complexity of the condition.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 3","pages":"rkae074"},"PeriodicalIF":2.1,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11193309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of trabecular bone score with disease parameters and vertebral fractures in axial spondyloarthritis.","authors":"Meryem Daflaoui, Hamida Azzouzi, Houssam Boutaibi, Fadoua Chennouf, Linda Ichchou","doi":"10.1093/rap/rkae071","DOIUrl":"10.1093/rap/rkae071","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to study trabecular bone score (TBS) association with disease parameters and vertebral fractures (VFs) in patients with axial spondyloarthritis.</p><p><strong>Methods: </strong>Patients diagnosed with axial spondyloarthritis were included in this cross-sectional study. Dual-energy X-ray absorptiometry was used to measure BMD in the lumbar spine and TBS. Low TBS was defined as ≤1.31. The association between TBS and disease parameters including Ankylosing Spondylitis Disease Activity Score (ASDAS), BASDAI, BASFI and BASMI was studied using logistic regressions.</p><p><strong>Results: </strong>Our study included 56 patients, with a mean age of 38.9 ± 13.5 years and a mean disease duration of 12.7 ± 7.7 years. Patients with low TBS were significantly older and had higher waist circumference and body mass index. These patients also showed greater clinical activity, as evidenced by higher ASDAS-CRP, BASFI and BASMI scores (<i>P</i> < 0.05). In multivariate logistic regression, low TBS was associated with all disease parameters, except for BASMI: BASDAI (OR [95% CI] = 3.68 [1.48-9.19], <i>P</i> = 0.005), ASDAS-CRP (OR [95% CI] = 2.92 [1.20-7.10], <i>P</i> = 0.018), BASFI (OR [95% CI] = 1.04 [1.01-1.08], <i>P</i> = 0.018), BASMI (OR [95% CI] = 1.36 [0.99-1.87], <i>P</i> = 0.062). However, no association was observed between TBS and VFs.</p><p><strong>Conclusion: </strong>TBS was associated with active spondyloarthritis, suggesting increased bone fragility in these patients. However, TBS failed to demonstrate an association with VFs.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 3","pages":"rkae071"},"PeriodicalIF":3.1,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11157133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141296609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trust performance in managing inflammatory arthritis over time in England and Wales: a latent class analysis approach.","authors":"Zijing Yang, Nikita Arumalla, Edward Alveyn, Sarah Gallagher, Elizabeth Price, Mark D Russell, Katie Bechman, Sam Norton, James Galloway","doi":"10.1093/rap/rkae053","DOIUrl":"10.1093/rap/rkae053","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate trust-level performance in time to initiation of DMARD therapy in patients with early inflammatory arthritis (EIA), with identification of the change in performance trajectories over time and investigation of trust characteristics associated with this change.</p><p><strong>Methods: </strong>We included 130 trusts from the UK contributing to the National Early Inflammatory Arthritis Audit (NEIAA) from 2018 to 2020. The primary outcome was days from referral to initiation of DMARD therapy in patients with EIA. Latent class growth mixture models were applied to identify distinct groups of trusts with similar trajectories of performance change over time. We used mixed effects linear and multinomial logistic regression models to evaluate the association between delay in treatment and trust-level characteristics.</p><p><strong>Results: </strong>The mean time to DMARD initiation was 53 days (s.d. 18), with an average 0.3-day decrease with each month over time. Four latent trajectories were identified in our cohort, with >77% of individual trusts showing ongoing improvements in decreasing treatment waiting times. Prior to separating by latent class, time to DMARD initiation was shorter in trusts with higher rheumatology staffing, a local EIA treatment pathway and those with access to musculoskeletal ultrasound. Trusts with more nurses in the rheumatology department were less likely to be in the worst performance group [odds ratio 0.69 (95% CI 0.49, 0.93)].</p><p><strong>Conclusion: </strong>In this cohort study, we observed a reduction in treatment waiting time over time. Trusts with better staffed and improved EIA clinical structure are likely to initiate definitive treatment earlier in patients with EIA.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 2","pages":"rkae053"},"PeriodicalIF":3.1,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141065791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}